2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/12hpyu88k-1qt.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/22x_afbr-hdp6.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T9b01,

Summary Table

Category	Details
Risk Factors	Age > 50 years, metabolic syndrome, obesity, hypertension, chronic inflammation, sedentary lifestyle, smoking, genetic predisposition, history of COVID-19 infection
Etiology	Histological proliferation of smooth muscle and epithelial cells in the transitional zone of the prostate, driven by dihydrotestosterone (DHT) activity via 5-alpha reductase (predominantly type 2)
Patient Presentation	Lower urinary tract symptoms (LUTS): weak stream, intermittency, incomplete emptying, frequency, urgency, nocturia, post-void dribbling; most severe presentation is urinary retention
Classic Physical Exam	Digital rectal examination (DRE) reveals a symmetrically enlarged, smooth, firm, non-tender, rubbery prostate without nodules; palpable/percussible bladder if retention is present
Key Diagnostic Results	Elevated IPSS (8-35), reduced Qmax on uroflowmetry (< 10-15 mL/s), increased post-void residual (PVR) on ultrasound, enlarged prostate volume on TAUS/TRUS, elevated PSA proportional to prostate volume, intravesical prostatic protrusion (IPP) grading
Management	Watchful waiting (IPSS < 7); alpha-1 blockers for moderate-severe LUTS; 5-alpha reductase inhibitors for prostate > 40 mL; combination therapy for high-risk progression; TURP (30-80 mL), prostatectomy/HoLEP (> 80 mL) for surgical candidates
Keywords	"Elderly male with difficulty urinating," "weak stream and nocturia," "smooth enlarged prostate on DRE," "post-void residual," "IPSS score," "obstructive and storage symptoms," "Qmax reduced"

1. Pathophysiology

BPH is a histological diagnosis defined by the proliferation of smooth muscle cells and epithelial cells within the transitional zone of the prostate. It is important to understand that the term "BPH" refers strictly to this histological pattern, while the clinical consequence of prostate enlargement is termed benign prostatic enlargement (BPE), and the functional obstruction it causes at the bladder outlet is called benign prostatic obstruction (BPO). These three terms are not interchangeable and test-writers may use them to assess conceptual precision.

The central hormonal driver is dihydrotestosterone (DHT), which is converted from testosterone by the enzyme 5-alpha reductase, predominantly the type 2 isoform found in prostatic tissue. DHT binds to androgen receptors within the prostate stroma and epithelium, promoting cellular proliferation and inhibiting apoptosis. This is why 5-alpha reductase inhibitors (finasteride, dutasteride) are effective in reducing prostate volume: they block the conversion of testosterone to DHT, thereby inducing apoptosis of prostatic epithelial cells.

The mechanical component of BPH arises because the expanding transitional zone compresses the prostatic urethra, increasing urethral resistance. This leads to voiding (obstructive) symptoms: weak stream, intermittency, straining, and incomplete emptying. The bladder detrusor muscle initially compensates by generating higher pressures during voiding (detrusor hypertrophy), but over time this compensation fails, leading to detrusor decompensation, increased post-void residual urine, and ultimately urinary retention.

The storage (irritative) symptoms, including frequency, urgency, and nocturia, arise from secondary changes in the bladder wall. Chronic obstruction leads to detrusor overactivity (DO), which is found in up to 61% of men with LUTS. This is why patients with BPH often present with both obstructive and irritative complaints simultaneously.

Chronic inflammation plays a contributory role. Studies show that prostatic tissue with severe inflammation is significantly larger than tissue with mild inflammation, driven by T-cell and mononuclear phagocyte infiltration producing proliferative cytokines (IL-2, IL-4, IL-7, INF-gamma) and growth factors (HB-EGF, bFGF/FGF-2). Obesity amplifies this inflammatory cascade, creating a cycle where inflammation promotes stromal and epithelial proliferation. This mechanism explains why metabolic syndrome and obesity are recognized modifiable risk factors for BPH progression.

2. Classification and Clinical Manifestation

LUTS Classification

LUTS	Symptoms	Mechanism
Voiding (Obstructive)	Weak stream, intermittency, straining, hesitancy, incomplete emptying, terminal dribbling	Mechanical compression of the prostatic urethra by enlarged transitional zone; increased urethral resistance
Storage (Irritative)	Frequency, urgency, nocturia, urge incontinence	Detrusor overactivity secondary to chronic obstruction; reduced functional bladder capacity
Post-micturition	Post-void dribbling, sensation of incomplete emptying	Residual urine in the prostatic urethra and decompensated detrusor

IPSS Severity

Severity	IPSS Score	Quality of Life Score	Clinical Implication
Mild	0 to 7	QoL score 0-2 (not bothersome)	Watchful waiting is appropriate
Moderate	8 to 19	QoL score > 2 (bothersome)	Medical therapy indicated
Severe	20 to 35	QoL score > 2 (bothersome)	Medical therapy or surgical intervention

According to the IAUI guideline, the decision to pursue active treatment is based not solely on the IPSS total score but also on the quality of life (QoL) score. If the QoL score on the IPSS is 2 or less (meaning the symptoms are not bothersome), the patient is managed conservatively regardless of the total IPSS. If the QoL score exceeds 2, symptoms are considered bothersome and the patient is directed toward medical or surgical management. This QoL-driven threshold is a key decision node in the IAUI diagnostic algorithm.

Intravesical Prostatic Protrusion (IPP) Grading

IPP Grade	Protrusion Size	Clinical Significance
Grade I	< 5 mm	Lower risk of acute urinary retention; better response to medical therapy
Grade II	5 to 10 mm	Moderate risk; correlates with higher IPSS voiding component scores
Grade III	> 10 mm	Strong correlation with acute urinary retention risk; poorer response to medical therapy; better symptom improvement post-surgery

IPP measured on transabdominal ultrasound has strong correlation with the risk of acute urinary retention and can predict outcomes of trial without catheter (TWOC), medical therapy response, and post-surgical symptom improvement. Patients with higher IPP grades tend to have more severe obstructive symptoms but also show more significant symptomatic improvement after surgical correction.

Frequency of Presenting Complaints in Indonesian BPH Patients

Complaint	Frequency Range
Difficulty voiding or urinary retention	55.5% to 59.6%
Increased urinary frequency	10.1% to 48%
Intermittent stream	7.9% to 34%
Straining to void	7.9% to 14%
Incomplete emptying	5.6% to 23%
Nocturia	3.4% to 44%

3. Diagnostic Workup

Test	Category	Purpose	Key Findings
History + IPSS	Mandatory, initial	Quantify symptom severity and bother	IPSS 0-7 mild, 8-19 moderate, 20-35 severe; QoL score determines if symptoms are bothersome
Digital Rectal Examination (DRE)	Mandatory, initial	Estimate prostate size, assess for malignancy	Smooth, symmetrically enlarged, firm, non-tender prostate; nodule or asymmetry raises suspicion of carcinoma
Urinalysis / Dipstick	Mandatory, initial	Rule out UTI, hematuria, diabetes, proteinuria	Positive nitrites/leukocytes suggest UTI; hematuria requires further evaluation
Renal Function (serum creatinine, eGFR)	Mandatory when indicated	Detect obstructive nephropathy	Elevated creatinine suggests chronic obstruction with upper tract damage
PSA	Recommended	Predict prostate volume, screen for carcinoma, predict disease progression	PSA > 1.4-1.6 ng/mL correlates with prostate volume > 40 mL; PSA > 4 ng/mL warrants biopsy discussion
Uroflowmetry	Recommended	Objectively measure voiding function	Qmax < 10 mL/s: 70% specificity and 70% PPV for BOO; Qmax < 15 mL/s: 82% sensitivity for BPH; valid only if voided volume > 150 mL
Post-Void Residual (PVR)	Recommended	Assess bladder emptying efficiency	PVR > 50 mL: PPV 63% and NPV 52% for BOO; serial increases in PVR predict risk of acute urinary retention
Ultrasound (TAUS/TRUS)	Recommended	Measure prostate volume, assess upper tracts, detect bladder stones/hydronephrosis, measure IPP	Volume guides treatment selection; IPP grade predicts TWOC success and medical therapy response
Voiding Diary	Recommended for storage-predominant symptoms	Differentiate nocturnal polyuria from BPH-related nocturia	Minimum 3 days; documents frequency, volume, nocturia pattern
Urethroc ystoscopy	Optional, before surgery	Evaluate for urethral stricture, bladder stones, bladder tumor	Indicated if hematuria, prior urethral surgery, or suspected bladder pathology
Urodynamics (PFS)	Optional	Confirm BOO vs. detrusor underactivity	Indicated when age < 50 or > 80, PVR > 300 mL, Qmax > 10 mL/s, post-pelvic surgery, or failed prior intervention

Step 1: History, IPSS, and Physical Examination. Every male patient over 40 presenting with LUTS should undergo a thorough history including assessment of urinary symptoms, sexual function, comorbidities, medication use (antihistamines, antidepressants, and bronchodilators are known to worsen IPSS by 2 to 3 points), and lifestyle factors. The IPSS questionnaire (validated in Indonesian) is then administered. The IPSS consists of seven questions scored 0 to 5 each, yielding a maximum of 35, plus one QoL question. A DRE is performed to estimate prostate size, assess consistency, and screen for malignancy. DRE tends to underestimate prostate volume, especially when the true volume exceeds 30 cc, but is sufficient to distinguish prostates above or below approximately 50 cc.

Step 2: Urinalysis and Renal Function. Urinalysis or dipstick is mandatory to exclude UTI, hematuria, diabetes, and proteinuria. Renal function testing (serum creatinine, eGFR) is indicated when there is clinical suspicion of renal impairment, hydronephrosis, or before planning surgery. One study cited in the guideline found that 11% of men with LUTS had renal dysfunction, and a significant negative correlation exists between Qmax and IPSS scores.

Step 3: PSA. PSA is measured in men over 50 (or over 40 in high-risk groups, such as those with a family history of prostate cancer). PSA serves a dual purpose: it is a strong predictor of prostate volume and growth rate (and therefore disease progression, risk of acute urinary retention, and need for surgery), and it aids in prostate cancer screening. The clinician must be aware that PSA can be elevated after DRE, acute retention, biopsy, TURP, and in prostatitis. When PSA exceeds 4 ng/mL, prostate biopsy should be discussed with the patient.

Step 4: Uroflowmetry and PVR. If symptoms are bothersome (QoL > 2), uroflowmetry and PVR measurement are performed. A Qmax below 10 mL/s has 70% specificity and 70% PPV for bladder outlet obstruction, while a threshold of 15 mL/s has 82% sensitivity for detecting BPH. The test is only valid when voided volume exceeds 150 mL. PVR is measured via ultrasound or bladder scan; an initial high PVR is associated with increased risk of symptom progression and acute retention. However, PVR alone has limited diagnostic accuracy (PPV 63%, NPV 52% at a 50 mL cutoff) and is best interpreted alongside uroflowmetry and prostate volume.

Step 5: Ultrasound. The IAUI guideline recommends ultrasound of the upper and lower urinary tract in all men with LUTS, partly because of the relatively high incidence of concomitant urolithiasis in Indonesian BPH patients (up to 31.5% in one West Java study). Ultrasound also measures prostate volume (critical for treatment selection) and IPP. TRUS provides more accurate volumetric assessment than TAUS but is more invasive.

Step 6: Selective Use of Cystoscopy and Urodynamics. Uretrocystoscopy is not routine but is indicated before invasive therapy if there is a history of hematuria, urethral stricture, or suspected bladder pathology. Urodynamics with pressure-flow studies is reserved for cases where the diagnosis is uncertain, such as in very young (< 50) or very old (> 80) patients, those with PVR > 300 mL, Qmax > 10 mL/s (where obstruction is uncertain), prior pelvic surgery, or failed initial intervention. The EAU and IAUI both categorize urodynamics as a weak recommendation due to its invasive nature and limited evidence for improving treatment outcomes.

4. Management and Treatment

Clinical Scenario	First-Line Therapy	Alternative/Adjunct	Notes
Mild LUTS (IPSS 0-7, QoL not bothersome)	Watchful waiting + lifestyle modification	None	79-85% clinically stable at 1 year; follow-up every 3-6 months
Moderate-Severe LUTS, small prostate (< 40 mL)	Alpha-1 blocker monotherapy	PDE-5 inhibitor (tadalafil 5 mg daily) if concomitant ED	Onset of action within days
Moderate-Severe LUTS, large prostate (> 40 mL), high progression risk	Combination alpha-1 blocker + 5-ARI	5-ARI monotherapy is not recommended by NICE 2021	Minimum 12 months of combination therapy; alpha-1 blocker withdrawal may be considered after 6-9 months in moderate symptoms
Storage-predominant LUTS not responding to alpha-1 blocker	Add antimuscarinic OR beta-3 agonist	Combination alpha-1 blocker + antimuscarinic	Contraindicated if PVR > 150 mL; monitor PVR regularly
LUTS with concomitant ED	Tadalafil 5 mg daily	Combination tadalafil + alpha-1 blocker (not recommended by AUA 2021)	Contraindicated with nitrates, nicorandil, doxazosin, terazosin
Surgical: prostate 30-80 mL	TURP (monopolar or bipolar)	Laser enucleation, laser vaporization, TUIP (< 30 mL without median lobe)	TURP is the gold standard; bipolar has better perioperative safety
Surgical: prostate > 80 mL	Open prostatectomy, HoLEP, or bipolar enucleation (TUEP-B)	Thulium enucleation	HoLEP/TUEP-B preferred when available due to better perioperative profile
Cannot undergo anesthesia	CIC, indwelling catheter, or permanent suprapubic cystostomy	None	Palliative approach
On anticoagulants that cannot be stopped	Laser vaporization (with caution)	HoLEP (safe on anticoagulants)	Use of laser in this setting requires careful consideration

Conservative Management (Watchful Waiting)

Watchful waiting is appropriate for patients with mild symptoms (IPSS < 7) or those with moderate symptoms who are not bothered by them. The guideline reports that approximately 79-85% of patients remain clinically stable at 1 year with conservative management, and self-management education reduces symptom severity and progression.

Lifestyle modifications to counsel patients on include: avoiding excessive fluid intake before bedtime, reducing caffeine, alcohol, and chocolate intake (which have diuretic and irritant effects), practicing double voiding (emptying the bladder again after a 5-minute interval), performing urethral milking (pressing along the penile urethra from base to meatus to prevent post-void dribbling), bladder training (gradually extending intervals between voids), and reviewing medications that worsen LUTS.

Follow-up is scheduled every 3 to 6 months with reassessment of IPSS, uroflowmetry, and PVR.

Medical Therapy

Medical therapy is indicated when the IPSS exceeds 7 and symptoms are bothersome.

Alpha-1 Blockers are the first-line pharmacotherapy for LUTS. Available agents include tamsulosin, silodosin (4 mg twice daily or 8 mg once daily, which are equally effective per the guideline), alfuzosin, doksazosin, and terazosin. These drugs relax smooth muscle in the prostate and bladder neck by blocking alpha-1 adrenoreceptors, reducing urethral resistance. They improve IPSS by 30-40% (4 to 6 point reduction) and increase Qmax by 20-25%. Onset of action is within a few days. However, they do not reduce prostate volume or the long-term risk of retention.

Key side effects: postural hypotension, dizziness, and asthenia (more common with non-selective agents like terazosin and doxazosin); retrograde ejaculation (more common with more selective agents like silodosin and tamsulosin); and intraoperative floppy iris syndrome (IFIS), which must be communicated to the patient and ophthalmologist before any planned cataract surgery.

An important clinical pearl from the guideline: intermittent dosing of doxazosin (alternate-day) showed no significant difference in efficacy compared to daily dosing.

5-Alpha Reductase Inhibitors (5-ARI) are indicated when the prostate volume exceeds 40 mL (finasteride) or 30 mL (dutasteride), or when PSA exceeds 1.4-1.6 ng/mL. Finasteride selectively inhibits type 2 5-alpha reductase, while dutasteride inhibits both types 1 and 2. These drugs reduce prostate volume by 18-28%, improve IPSS by 15-30%, and increase Qmax over 2 to 4 years of treatment. They also reduce the risk of acute urinary retention and need for surgery. The critical caveat is that clinical effect takes 3 to 6 months to manifest, making them unsuitable for short-term use. They must be prescribed for long-term therapy (years). Side effects include erectile dysfunction, decreased libido, retrograde ejaculation, decreased semen volume, and gynecomastia. Importantly, 5-ARI reduce PSA by approximately 50%, so PSA values must be adjusted (doubled) when screening for prostate cancer in patients on these drugs. NICE 2021 does not recommend 5-ARI monotherapy.

Combination Alpha-1 Blocker + 5-ARI is the recommended approach for patients with moderate-to-severe LUTS who have a large prostate (> 40 mL) and are at risk of disease progression. The landmark MTOPS and CombAT trials showed that combination therapy is superior to either monotherapy for symptom improvement, Qmax improvement, and reducing the risk of acute urinary retention and need for surgery. The CombAT study demonstrated a 68% relative risk reduction for acute retention, 71% for BPH-related surgery, and 41% for symptom deterioration compared to tamsulosin alone after 4 years. This combination is only recommended for long-term use (> 12 months). After 6 to 9 months, withdrawal of the alpha-1 blocker may be considered in patients with moderate symptoms, though patients with severe baseline symptoms (IPSS > 20) benefit from longer combination therapy. A fixed-dose combination of dutasteride and tamsulosin is available and associated with improved medication adherence.

Antimuscarinics (solifenacin, tolterodine, fesoterodine, propiverine) target storage symptoms by blocking M2 and M3 receptors on the detrusor. They are considered when alpha-1 blocker monotherapy fails to relieve storage symptoms. They should not be used when PVR exceeds 150 mL due to the risk of acute urinary retention. Regular monitoring of IPSS and PVR is required.

Beta-3 Agonists (mirabegron 25-50 mg daily) relax the detrusor by stimulating beta-3 adrenergic receptors. They improve OAB symptoms (frequency, urgency, nocturia, urge incontinence) and have a better tolerability profile than antimuscarinics, especially in patients over 65 years. Mirabegron is contraindicated in uncontrolled hypertension.

PDE-5 Inhibitors (tadalafil 5 mg daily) reduce smooth muscle tone in the detrusor, prostate, and urethra via increased intracellular cGMP. Tadalafil decreases IPSS by 22-37%, with meaningful improvement seen within one week. However, it does not significantly improve Qmax compared to placebo. It is particularly useful in patients with concomitant erectile dysfunction. Contraindications include use of nitrates, nicorandil, and non-selective alpha blockers (doxazosin, terazosin). It is also contraindicated in unstable angina, recent MI (< 3 months), or recent stroke (< 6 months). The AUA 2021 does not recommend combining tadalafil with alpha blockers.

Phytotherapy is not recommended by the IAUI, consistent with international guidelines including NICE 2021, which advises against homeopathy, phytotherapy, or acupuncture for LUTS/BPH.

Surgical Management

Surgery is indicated for absolute indications (acute urinary retention, failed TWOC, recurrent UTI, recurrent gross hematuria, bladder stones, obstructive nephropathy, or pathological changes in the bladder and upper tracts) or relative indications (moderate-to-severe symptoms unresponsive to medical therapy, or patient preference for active intervention).

TURP (Monopolar or Bipolar) remains the surgical gold standard for prostate volumes of 30 to 80 mL. It improves symptoms by up to 90% and doubles Qmax. TURP-Bipolar uses normal saline irrigation (eliminating the risk of TUR syndrome), has similar long-term efficacy to monopolar TURP, and has a better perioperative safety profile (less bleeding, shorter catheterization, shorter hospital stay). Bipolar is also safe in patients with cardiac pacemakers. Complications include bleeding requiring transfusion (0-9%), TUR syndrome (0-5%, monopolar only), retrograde ejaculation (65.4%), urethral stricture (3.8%), bladder neck stenosis (4.7%), incontinence (2.2%), and erectile dysfunction (6.5-14%). The 30-day mortality rate is 0.1%.

TUIP is reserved for prostates < 30 mL without median lobe enlargement. It has similar efficacy to TURP for symptom relief but a higher reoperation rate (18.4% vs. 7.2%) and lower retrograde ejaculation rate.

Open Prostatectomy (transvesical Freyer or retropubic Millin) is indicated for prostates > 80-100 mL when endoscopic enucleation (HoLEP, TUEP-B) is not available. It reduces IPSS by 63-86%, improves Qmax by up to 375%, and has durable results. It carries more blood loss, longer catheterization, and longer hospital stays compared to endoscopic alternatives. Mortality has decreased to < 0.25%.

HoLEP (Holmium Laser Enucleation of the Prostate) is an alternative to both TURP and open prostatectomy, suitable for any prostate size. It has comparable long-term efficacy to TURP and open prostatectomy with a better perioperative profile (less blood loss, shorter catheterization). It is safe in patients on anticoagulants. The main disadvantage is a steeper learning curve and longer operative time.

TUEP-B (Bipolar Transurethral Enucleation) shows superior medium-to-long-term efficacy compared to TURP, with a better perioperative safety profile.

Laser Vaporization (PVP/Greenlight, Thulium) is an alternative for prostates 30 to 80 mL and is particularly considered for patients on anticoagulants or antiplatelets that cannot be discontinued, though the guideline advises careful consideration in this setting.

TWOC (Trial Without Catheter) is performed for first-episode acute urinary retention before a definitive diagnosis is established. An alpha-1 blocker must be given for a minimum of 3 to 7 days before catheter removal. A study at RS Soetomo showed that combining tamsulosin 0.4 mg daily with meloxicam 15 mg for 7 days improved TWOC success rates compared to tamsulosin alone.

Follow-Up Schedule

Therapy	Initial Follow-Up	Subsequent Follow-Up
Alpha-1 blocker, antimuscarinic, beta-3 agonist, PDE-5 inhibitor, combination alpha-1 blocker + antimuscarinic	4 to 6 weeks post-initiation	If improved without significant side effects: 6 months, then annually
5-ARI (alone or in combination)	12 weeks, then 6 months post-initiation	PSA monitoring every 6 months if life expectancy > 10 years; any PSA rise during 5-ARI therapy must be evaluated
Post-surgical	4 to 6 weeks after catheter removal	Only if symptoms persist or complications arise

5. Differential Diagnosis and Distractors

Differential	Why It Is Similar	Key Discriminator
Prostate Cancer	Older male with LUTS; elevated PSA; enlarged prostate on DRE	DRE reveals a hard, irregular, nodular prostate (vs. smooth and rubbery in BPH); PSA disproportionately elevated relative to prostate volume; biopsy is confirmatory
Urethral Stricture	Obstructive voiding symptoms (weak stream, straining, incomplete emptying)	History of prior urethral instrumentation, trauma, STI, or surgery; retrograde urethrography shows narrowing; younger patient demographic
Overactive Bladder (OAB)	Storage symptoms (urgency, frequency, nocturia, urge incontinence)	Predominantly storage symptoms without significant obstructive symptoms; normal prostate on DRE; normal Qmax on uroflowmetry; no elevated PVR
Neurogenic Bladder	Voiding dysfunction with both storage and voiding symptoms; elevated PVR	History of neurological disease (stroke, Parkinson, spinal cord injury, diabetes neuropathy); abnormal sacral reflexes on DRE (bulbocavernosus reflex, perianal reflex); urodynamics showing detrusor-sphincter dyssynergia
Chronic Prostatitis / CPPS	LUTS in a middle-aged male; may have elevated PSA	Pelvic/perineal pain is the dominant symptom; tenderness on DRE; normal prostate size; positive urine cultures or expressed prostatic secretion; younger age group
Bladder Cancer	Hematuria in an older male with irritative LUTS	Painless gross hematuria is the cardinal symptom; risk factors include smoking, occupational carcinogen exposure; cystoscopy and urine cytology are diagnostic
Urinary Tract Infection	Frequency, urgency, dysuria	Positive urinalysis (pyuria, bacteriuria, positive nitrites); fever if pyelonephritis; acute onset; responds to antibiotics
Nocturnal Polyuria	Nocturia as a prominent symptom	Voiding diary shows > 33% of 24-hour urine output produced at night; normal daytime voiding frequency and volume; no obstructive symptoms
Medication-Induced LUTS	LUTS symptoms in a patient on certain medications	History of antihistamine, anticholinergic, sympathomimetic, or antidepressant use; IPSS may increase by 2-3 points; symptom improvement after medication adjustment

6. Traps and High-Yield Pearls

The most common trap in exam questions about BPH is confusing the terminology: BPH (a histological diagnosis), BPE (a clinical finding of prostate enlargement), and BPO (a functional diagnosis of obstruction). A vignette may describe a patient with LUTS and ask for the best terminology or the best next diagnostic step, expecting you to recognize that LUTS alone does not equal BPH.

A second frequent mistake is selecting 5-ARI monotherapy for a patient with moderate LUTS but a small prostate (< 30-40 mL). The 5-ARIs are only effective in patients with an enlarged prostate (> 40 mL) or elevated PSA (> 1.4-1.6 ng/mL), and they require 3 to 6 months before clinical benefit is seen. Choosing finasteride for a patient who needs rapid symptom relief, or for a prostate under 40 mL, is a classic error.

A third trap involves the QoL threshold. The IAUI algorithm uses the QoL score on the IPSS (not the total IPSS alone) as the decision node: a total IPSS of 12 with a QoL of 1 is managed conservatively, while an IPSS of 9 with a QoL of 4 warrants active treatment. Test-writers may present a patient with a "moderate" IPSS but an unbothered QoL score to test whether you correctly select watchful waiting.

Fourth, remember that uroflowmetry results are only valid when the voided volume exceeds 150 mL. A vignette may present a low Qmax with a voided volume of 80 mL, and the correct answer is to repeat the test, not to diagnose obstruction.

Fifth, students often forget the drug interaction between alpha-1 blockers and cataract surgery. If a patient on tamsulosin is referred for cataract surgery, the examiner is testing whether you recognize the risk of IFIS and counsel both the patient and the ophthalmologist accordingly.

Finally, when the vignette presents a BPH patient on anticoagulants who needs surgery, the expected answer is laser-based procedures (HoLEP, PVP) rather than conventional TURP, because laser techniques offer superior hemostasis, although the guideline notes this should be approached with caution.

The core competency being tested in BPH questions is the ability to match the right treatment to the right patient profile: prostate size, symptom severity, QoL impact, comorbidities, and medication use all determine the next best step. Memorizing the treatment algorithm, especially the volume thresholds (< 30 mL for TUIP, 30-80 mL for TURP, > 80 mL for open prostatectomy/HoLEP), and knowing which drugs require which minimum prostate volume, will cover the majority of exam items on this topic.

1e:["$","$L2d",null,{"article":{"id":"89927e77-884e-4e09-8a45-be80db0483c1","title":"Benign Prostatic Hyperplasia (BPH)","content":"$2e","category":"Uronefrologi","created_at":"2026-08-21T06:38:51.74994+00:00","status":"published","subcategory":null},"questionCount":1,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]